Evidence map›Paper›PMID 36682125›Full record

ArticleStem cell research2023

Using CRISPR/Cas9 to generate a heterozygous COL2A1 p.R719C iPSC line (MCRIi019-A-6) model of human precocious osteoarthritis.

Kathryn M Yammine, Sophia Mirda Abularach, Lisa Sampurno, John F Bateman, Shireen R Lamandé, Matthew D Shoulders

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cell research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Failed Cellular Surveillance Enables Pathogenic Matrix Deposition in abioRxiv : the preprint server for biology · 2025
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Kathryn M YammineDepartment of Chemistry, Massachusetts Institute of Technology, United States.
Sophia Mirda AbularachDepartment of Chemistry, Massachusetts Institute of Technology, United States.
Lisa SampurnoMurdoch Children's Research Institute, Australia.
John F BatemanMurdoch Children's Research Institute, Australia; Department of Paediatrics, University of Melbourne, Australia.
Shireen R LamandéMurdoch Children's Research Institute, Australia; Department of Paediatrics, University of Melbourne, Australia.
Matthew D ShouldersDepartment of Chemistry, Massachusetts Institute of Technology, United States. Electronic address: mshoulde@mit.edu.
Massachusetts Institute of Technology · USThe University of Melbourne · AUMurdoch Children's Research Institute · AU

Funding

Defining and Modulating Mechanisms of Collagen ProteostasisR01AR071443 · NIAMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI SHOULDERS, MATTHEW DONALD · 2017 to 2021
$1.7M
Chondronoids for Studying Collagen-II Homeostasis and DiseasesF31AR079263 · NIAMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI YAMMINE, KATHRYN · 2021 to 2023
$140k
NIAMS NIH HHS F31 AR079263NIAMS NIH HHS R01 AR071443
6 · The paper itself

Abstract

The human iPSC line MCRIi019-A-6 was generated using CRISPR/Cas9-mediated gene editing to introduce a heterozygous COL2A1 exon 33 c.2155C>T (p.R719C) mutation into the control human iPSC line MCRIi019-A. Both the edited and parental lines display typical iPSC characteristics, including the expression of pluripotency markers, the ability to be differentiated into the three germ lines, and a normal karyotype. This cell line, along with the isogenic control line, can be used to study the molecular pathology of precocious osteoarthritis in a human model, more broadly understand type II collagenopathies, and explore novel therapeutic targets for this class of diseases.

Indexed as

Induced Pluripotent Stem CellsOsteoarthritisCollagen Type IICRISPR-Cas SystemsGene EditingHeterozygoteHumansMutationCOL2A1 protein, humanCollagen Type II

Identifiers

PMID36682125
PMCPMC10038005
OpenAlexW4313644997

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.